S.Biomedics Co., Ltd. (KOSDAQ:304360)

South Korea flag South Korea · Delayed Price · Currency is KRW
36,850
+2,250 (6.50%)
At close: Apr 29, 2026
Market Cap447.10B +64.8%
Revenue (ttm)16.55B +20.5%
Net Income-8.12B
EPS-684.07
Shares Out12.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume148,421
Average Volume79,236
Open34,850
Previous Close34,600
Day's Range34,350 - 37,000
52-Week Range17,930 - 42,600
Beta1.53
RSI63.96
Earnings DateApr 6, 2026

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 304360
Full Company Profile

Financial Performance

In 2025, S.Biomedics's revenue was 16.55 billion, an increase of 20.49% compared to the previous year's 13.73 billion. Losses were -8.12 billion, 21.4% more than in 2024.

Financial Statements